RELN and non-small cell lung carcinoma: Survival analysis revealed that a significantly improved ICI survival benefit was found in NSCLC patients with RELN mutations (median survival time: 23.0 vs. 6.27 months, Log-rank test p = 0.003; Figure 3A).